• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

June 7, 2021
Company Drug/Device Medical Condition Status
Breegi Scientific Negative Pressure SteriDome protection from airborne pathogens in hospitalized patients with suspected or confirmed diagnosis of COVID-19 Emergency Use Authorization (EUA) granted by the FDA
GlaxoSmithKline

Vir Biotechnology
sotrovimab mild-to-moderate COVID-19 in adults and pediatric patients who are at high risk for progression to severe COVID-19 EUA granted by the FDA
Asklepios BioPharmaceutical LION-101 limb-girdle muscular dystrophy type 2I/R9 IND approved by the FDA
Dicerna Pharmaceuticals

Eli Lilly
LY3819469 cardiometabolic diseases IND approved by the FDA
Merakris Therapeutics dermacyte amniotic wound care liquid nonhealing venous stasis ulcers IND approved by the FDA
Scopus Biopharma CpG-STAT3siRNA B-cell nonHodgkins lymphoma IND approved by the FDA
Tarus Therapeutics TT-4 advanced solid tumors IND approved by the FDA
Transgene

BioInvent
BT-001 solid tumors IND approved by the FDA
AffaMed Therapeutics AM006 early Parkinson's disease clinical trial application (CTA) approved by China's National Medical Products Administration for phase 2b trial
Ryvu Therapeutics RVU120 (SEL120) relapsed/refractory metastatic or advanced solid tumors CTA approved in Poland
Acutis Medical AcQBlate Force Sensing ablation catheter and system paroxysmal and persistent atrial fibrillation Investigational Device Exemption approved by the FDA
Alkermes Lybalvi (olanzapine and samidorphan) schizophrenia and bipolar 1 disorder approved by the FDA
Amgen Lumakras (sotorasib) adult patients with KRAS G12C-mutated locally advanced or metastatic nonsmall-cell lung cancer approved by the FDA
Biohaven Pharmaceutical Nurtec ODT (rimegepant ) preventive treatment of migraine approved by the FDA for new formulation
BridgeBio Pharma

QED Therapeutics

Helsinn Group
Truseltiq (infigratinib) patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement approved by the FDA
Bristol-Myers Squibb Zeposia (ozanimod) moderately- to severely-active ulcerative colitis approved by the FDA
Forsee Pharmaceuticals Camcevi (ready-to-use six-month subcutaneous depot formulation of leuprolide mesylate) advanced prostate cancer approved by the FDA
Janssen Pharmaceutical Rybrevant (amivantamab-vmjw) adult patients with locally advanced or metastatic nonsmall-cell lung cancer with EGFR exon 20 insertion mutations approved by the FDA
Merck

Sanofi Pasteur
Vaxelis vaccine against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and invasive disease due to haemophilus influenzae type b for use in children six weeks through four years of age approved by the FDA
Myovant Sciences

Pfizer
Myfembree(relugolix, estradiol and norethindrone acetate) heavy menstrual bleeding associated with uterine fibroids in premenopausal women approved by the FDA
Novartis Cosentyx (secukinumab) moderate-to-severe plaque psoriasis in pediatric patients six years and older approved by the FDA for expanded indication
Paratek Pharmaceuticals Nuzyra (omadacycline) community-acquired bacterial pneumonia approved by the FDA for new formulation
Scynexis Brexafemme (ibrexafungerp tablets) vulvovaginal candidiasis approved by the FDA
ITO D Function electrical muscle stimulator for TMJ pain relief approved by the FDA
JenaValve Technology Trilogy heart valve system aortic regurgitation and aortic stenosis approved by the FDA
Lantheus Holdings Pylarify prostate-specific membrane antigen-targeted PET imaging agent approved by the FDA

 

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing